Global Finance News
03 Mar 2025, 17:18
Boston Scientific has entered into an agreement to acquire SoniVie Ltd., a medical device company that developed the TIVUS Intravascular Ultrasound System. This investigational technology is designed to treat hypertension by denervating nerves surrounding blood vessels, specifically through renal artery denervation. The acquisition expands Boston Scientific’s interventional cardiology portfolio with an ultrasound-based alternative to existing renal denervation therapies.
Hypertension is a leading risk factor for cardiovascular disease, and existing treatments, including medications and lifestyle changes, are often insufficient. The TIVUS system uses ultrasound energy to penetrate tissue more deeply than radiofrequency-based methods, potentially enabling faster procedures with effective nerve ablation.
Boston Scientific currently holds a 10% equity stake in SoniVie. The acquisition involves an upfront payment of approximately $360 million for the remaining 90%, with up to $180 million in additional payments contingent on regulatory milestones. The transaction is expected to close in the first half of 2025. The company anticipates a slight dilutive effect on adjusted earnings in 2025, offset by internal cost efficiencies.
The TIVUS system remains an investigational device and is not yet approved for commercial use. Boston Scientific continues to expand its portfolio of innovative cardiovascular treatments through strategic acquisitions.
Hypertension is a leading risk factor for cardiovascular disease, and existing treatments, including medications and lifestyle changes, are often insufficient. The TIVUS system uses ultrasound energy to penetrate tissue more deeply than radiofrequency-based methods, potentially enabling faster procedures with effective nerve ablation.
Boston Scientific currently holds a 10% equity stake in SoniVie. The acquisition involves an upfront payment of approximately $360 million for the remaining 90%, with up to $180 million in additional payments contingent on regulatory milestones. The transaction is expected to close in the first half of 2025. The company anticipates a slight dilutive effect on adjusted earnings in 2025, offset by internal cost efficiencies.
The TIVUS system remains an investigational device and is not yet approved for commercial use. Boston Scientific continues to expand its portfolio of innovative cardiovascular treatments through strategic acquisitions.
